CARLSBAD, Calif., Sept. 20 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS - News) announced today that the United States Patent and Trademark Office (USPTO) has issued to Isis U.S. Patent No. 7,108,974 (the ‘974 Patent), a fundamental patent covering the bacterial identification methodology used in the Ibis T5000(TM) biosensor system developed and being commercialized by the Company’s Ibis division. The ‘974 Patent broadly covers identification of bacterial organisms obtained by analyzing molecular signatures derived from the organism’s DNA.
